Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.

This article has no abstract
Epistemonikos ID: f66121ddf8b367bbbf88a08efaccdb0602fa2ef1
First added on: Apr 04, 2025